Coverage of atypical antipsychotics among medicare drug plans in the State of Washington for fiscal year 2007

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 10, Issue 4, 2008, Pages 313-317

  Wang, Chi Chuan ^a   Kennedy, Jae ^b   Cohen, Lawrence J ^b,c   Sclar, David A ^b,c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

^c Washington Institute for Mental Illness Research and Training   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; DRUG COST; LOWEST INCOME GROUP; MEDICARE;

EID: 49449086874     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.v10n0407     Document Type: Article

References (29)

1. Cohen LJ. Looking beyond the formulary budget in cost-benefit analysis. Am J Manag Care 1997 Feb;3(suppl):S11-S17
2. Anderson PO, Knoben JE, Troutman WG. Handbook of Clinical Drug Data. New York, NY: McGraw-Hill; 2002
3. Stahl SM. Essential Psychopharmacology of Antipsychotics and Mood Stabilizers. New York, NY: Cambridge University Press; 2002
4. Tunis SL, Faries DE, Nyhuis AW, et al. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial. Value Health 2006 Mar-Apr;9(2):77-89
5. Glazer WM. Formulary decisions and health economics. J Clin Psychiatry 1998;59(suppl 19):23-29
6. Taylor DM, Young C, Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry 2003 Jan;64(1):30-34
7. Advokat CD, Bertman LJ, Comaty JE Jr. Clinical outcome to clozapine treatment in chronic psychiatric inpatients. Prog Neuropsychopharmacol Biol Psychiatry 1999 Jan;23(1):1-14
8. Mauri MC, Volonteri LS, Dell'Osso B, et al. Predictors of clinical outcome in schizophrenic patients responding to clozapine. J Clin Psychopharmacol 2003 Dec;23(6):660-664
9. Bach PB, McClellan MB. A prescription for a modern Medicare program. N Engl J Med 2005 Dec;353(26):2733-2735
10. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 Sep;353(12):1209-1223
11. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006 Oct;63(10):1079-1087
12. Lewis SW, Barnes TR, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006 Oct;32(4):715-723
13. Moffic HS. Ethical principles for psychiatric administrators: the challenge of formularies. Psychiatr Q 2006;77(4):319-327
14. Rosack J. CMS acknowledges need for inclusive part D formulary. Psychiatr News 2006 Mar;41(6):1-8
15. Huskamp HA, Stevenson DG, Donohue JM, et al. Coverage and prior authorization of psychotropic drugs under Medicare Part D. Psychiatr Serv 2007 Mar;58(3):308-310
16. Usdin S. Medicare Part D: an overview of its practical and clinical impact. Am J Geriatr Cardiol 2005 Nov-Dec;14(6):284-288
17. Gold M. Premiums and Cost-Sharing Features in Medicare's New Prescription Drug Program, 2006. The Henry J. Kaiser Family Foundation. Available at: http://www.kff.org/medicare/upload/7517.pdf. Accessed 6-25-08
18. Andersen LS. Prescription drug benefits under Part D of the Medicare Modernization Act: the genie's out of the bottle. Issue brief 2005;5(10):1-10
19. Huskamp HA, Keating NL. The new Medicare drug benefit: formularies and their potential effects on access to medications. J Gen Intern Med 2005 Jul;20(7):662-665
20. Donohue JM. Economic grand rounds: the economics of the new Medicare drug benefit: implications for people with mental illnesses. Psychiatr Serv 2005 Jun;56(6):645-647
21. Huskamp HA, Deverka PA, Epstein AM, et al. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med 2003 Dec;349(23):2224-2232
22. Maio V, Pizzi L, Roumm AR, et al. Pharmacy utilization and the Medicare Modernization Act. Milbank Q 2005;83(1):101-130
23. Sethi RC. Prescription drugs: recent trends in utilization, expenditures, and coverage. EBRI Issue Brief 2004 Jan;(265):1-35
24. Goodwin FK. Impact of formularies on clinical innovation. J Clin Psychiatry 2003;64(suppl 17):11-14
25. Heisler M, Langa KM, Eby EL, et al. The health effects of restricting prescription medication use because of cost. Med Care 2004 Jul;42(7):626-634
26. Leslie DL, Rosenheck RA. From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications. Am J Psychiatry 2002 Sep;159(9):1534-1540
27. Lazarus A. Impact of formulary restrictions on patient safety. Physician Exec 2005 Jul-Aug;31(4):42-44
28. Wickersham RM, Novak KK, eds. Drug Facts and Comparisons. St. Louis, Mo: Wolters Kluwer Health, Inc; 2005
29. Prescription Drug Coverage. Medicare Prescription Drug Plan Finder. Available at: http://www.medicare.gov/pdphome.asp. Accessed 6-25-08